ABSTRACT
BACKGROUND: The soluble isoform of the interferon-ß (IFN-ß) receptor (sIFNAR2) could modulate the activity of both endogenous and systemically administered IFN-ß. Previously, we described lower serum sIFNAR2 levels in untreated multiple sclerosis (MS) than in healthy controls (HCs). OBJECTIVE: To assess sIFNAR2 levels in a new cohort of MS patients and HCs, as well as in patients with clinically isolated syndrome (CIS) and with other inflammatory neurological disorders (OIND) and to assess its ability as a diagnostic biomarker. METHODS: The cross-sectional study included 148 MS (84 treatment naive and 64 treated), 87 CIS, 42 OIND, and 96 HCs. Longitudinal study included 94 MS pretreatment and after 1 year of therapy with IFN-ß, glatiramer acetate (GA), or natalizumab. sIFNAR2 serum levels were measured by a quantitative ELISA developed and validated in our laboratory. RESULTS: Naive MS and CIS patients showed significantly lower sIFNAR2 levels than HCs and OIND patients. The sensitivity and specificity to discriminate between MS and OIND, for a sIFNAR2 cutoff value of 122.02 ng/mL, were 70.1%, and 79.4%, respectively. sIFNAR2 increased significantly in IFN-ß-treated patients during the first year of therapy in contrast to GA- and natalizumab-treated patients who showed non-significant changes. CONCLUSION: The results suggest that sIFNAR2 could be a potential diagnostic biomarker for MS.
Subject(s)
Multiple Sclerosis/blood , Receptor, Interferon alpha-beta/blood , Adult , Aged , Biomarkers/blood , Case-Control Studies , Cross-Sectional Studies , Down-Regulation , Enzyme-Linked Immunosorbent Assay , Female , Glatiramer Acetate/therapeutic use , Humans , Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Longitudinal Studies , Male , Middle Aged , Multiple Sclerosis/diagnosis , Multiple Sclerosis/drug therapy , Natalizumab/therapeutic use , Predictive Value of Tests , Reproducibility of Results , Time Factors , Treatment OutcomeABSTRACT
AIM: The soluble isoform of the IFN-ß receptor (sIFNAR2) can bind IFN-ß and modulate its activity, although its role in autoimmune diseases remains unknown. METHODS: A recombinant human sIFNAR2 protein was cloned, expressed and purified after which we developed and validated an ELISA for its quantification in human serum. Serum sIFNAR2 were assessed in multiple sclerosis (MS) patients and healthy controls. RESULTS: The ELISA has a dynamic range of 3.9-250 ng/ml and a detection limit of 2.44 ng/ml. Serum sIFNAR2 were significantly lower in untreated-MS patients than in healthy controls. CONCLUSION: The ELISA is suitable for quantification of sIFNAR2 in serum and should facilitate the study of sIFNAR2 in neuroimmunological diseases such as MS.
Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Multiple Sclerosis/diagnosis , Receptor, Interferon alpha-beta/blood , Recombinant Proteins/metabolism , Case-Control Studies , Humans , Multiple Sclerosis/blood , Reproducibility of ResultsABSTRACT
BACKGROUND: Both the adaptative and the innate immune systems interplay in multiple sclerosis (MS) pathogeny. Killer-cell immunoglobulin-like receptors (KIRs) are key regulators of the immune response, with activating and inhibitory isoforms. OBJECTIVE: In this study we analysed whether the expression of KIR isoforms is implicated in MS pathogenesis and in the therapeutic response to interferon (IFN)-ß. METHODS: Peripheral blood samples were collected from 78 IFN-ß-treated MS patients and 46 healthy controls (HC). KIR expression was evaluated by flow cytometry on natural killer (NK) and T cells. RESULTS: The expression of KIRs on NK cells and T lymphocytes did not differ between MS patients and HC. IFN-ß therapy decreased the expression of KIR2DL1/2DS1 and increased that of KIR2DL2/3 on NK cells. This therapy also reduced KIR2DL1/2DS1, KIR2DL2/2DL3 and KIR3DL2 expression on CD8(+) T cells. The baseline evaluation of the percentage of circulating CD16(+) NK cells was predictive of the clinical response to IFN-ß; however, response to this therapy did not appear related to KIR expression. CONCLUSIONS: This study shows that expression of KIR isoforms on NK and T lymphocytes correlated in different ways with IFN-ß therapy, suggesting that KIR dynamics may be associated with the pathways involved in the mechanisms of action of IFN-ß.
Subject(s)
Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Multiple Sclerosis, Chronic Progressive/drug therapy , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Receptors, KIR/genetics , Adaptive Immunity/drug effects , Adult , Biomarkers/blood , Female , Flow Cytometry , GPI-Linked Proteins/immunology , Humans , Immunity, Innate/drug effects , Immunologic Factors/administration & dosage , Interferon-beta/administration & dosage , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Male , Multiple Sclerosis, Chronic Progressive/blood , Multiple Sclerosis, Chronic Progressive/immunology , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/immunology , Predictive Value of Tests , Receptors, IgG/immunology , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/immunology , Time Factors , Treatment OutcomeABSTRACT
TRAIL and TRAIL Receptor genes have been implicated in Multiple Sclerosis pathology as well as in the response to IFN beta therapy. The objective of our study was to evaluate the association of these genes in relation to the age at disease onset (AAO) and to the clinical response upon IFN beta treatment in Spanish MS patients. We carried out a candidate gene study of TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 and TRAILR-4 genes. A total of 54 SNPs were analysed in 509 MS patients under IFN beta treatment, and an additional cohort of 226 MS patients was used to validate the results. Associations of rs1047275 in TRAILR-2 and rs7011559 in TRAILR-4 genes with AAO under an additive model did not withstand Bonferroni correction. In contrast, patients with the TRAILR-1 rs20576-CC genotype showed a better clinical response to IFN beta therapy compared with patients carrying the A-allele (recessive model: pâ=â8.88×10(-4), pcâ=â0.048, ORâ=â0.30). This SNP resulted in a non synonymous substitution of Glutamic acid to Alanine in position 228 (E228A), a change previously associated with susceptibility to different cancer types and risk of metastases, suggesting a lack of functionality of TRAILR-1. In order to unravel how this amino acid change in TRAILR-1 would affect to death signal, we performed a molecular modelling with both alleles. Neither TRAIL binding sites in the receptor nor the expression levels of TRAILR-1 in peripheral blood mononuclear cell subsets (monocytes, CD4+ and CD8+ T cells) were modified, suggesting that this SNP may be altering the death signal by some other mechanism. These findings show a role for TRAILR-1 gene variations in the clinical outcome of IFN beta therapy that might have relevance as a biomarker to predict the response to IFN beta in MS.